MX2009011473A - Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. - Google Patents

Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.

Info

Publication number
MX2009011473A
MX2009011473A MX2009011473A MX2009011473A MX2009011473A MX 2009011473 A MX2009011473 A MX 2009011473A MX 2009011473 A MX2009011473 A MX 2009011473A MX 2009011473 A MX2009011473 A MX 2009011473A MX 2009011473 A MX2009011473 A MX 2009011473A
Authority
MX
Mexico
Prior art keywords
dosing regimens
lysosomal storage
treatment
pharmacological chaperones
storage diseases
Prior art date
Application number
MX2009011473A
Other languages
English (en)
Inventor
Brandon Wustman
David Lockhart
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2009011473A publication Critical patent/MX2009011473A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La presente invención proporciona regímenes de dosificación para administrar chaperonas farmacológicas a un sujeto que lo necesite. Los regímenes de dosificación se pueden utilizar para tratar trastornos causados por un mal plegamiento de proteínas inadecuado, tales como trastornos por almacenamiento lisosomal.
MX2009011473A 2007-04-26 2008-04-28 Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. MX2009011473A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91428807P 2007-04-26 2007-04-26
US1474407P 2007-12-18 2007-12-18
US2810508P 2008-02-12 2008-02-12
PCT/US2008/061764 WO2008134628A2 (en) 2007-04-26 2008-04-28 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones

Publications (1)

Publication Number Publication Date
MX2009011473A true MX2009011473A (es) 2010-01-18

Family

ID=39926311

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011473A MX2009011473A (es) 2007-04-26 2008-04-28 Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.

Country Status (8)

Country Link
US (2) US9056101B2 (es)
EP (1) EP2150254A4 (es)
JP (1) JP2010525084A (es)
AU (1) AU2008245578A1 (es)
CA (1) CA2685332A1 (es)
IL (1) IL201733A0 (es)
MX (1) MX2009011473A (es)
WO (1) WO2008134628A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332567B1 (en) 2003-01-31 2015-04-08 The Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
ES2464527T7 (es) 2006-05-16 2015-09-14 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
PL2946785T3 (pl) 2008-02-12 2019-04-30 Amicus Therapeutics Inc Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi
BR122019024895B8 (pt) 2008-06-26 2021-07-27 Orphazyme As uso de um agente bioativo capaz de aumentar a concentração intracelular de hsp70
WO2010048532A1 (en) 2008-10-24 2010-04-29 Amicus Therapeutics, Inc. Multiple compartment dosing model
US20100119502A1 (en) * 2008-11-11 2010-05-13 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
BRPI1010517A2 (pt) * 2009-04-09 2017-01-31 Amicus Therapeutics Inc métodos para prevenção e/ou tratamento de doenças de armazenamento lisossomal
GB0906159D0 (en) * 2009-04-09 2009-05-20 Summit Corp Plc Drug combination for the treatment of proteostatic diseases
US9044437B2 (en) * 2009-10-19 2015-06-02 Amicus Therapeutics, Inc. Method for treating alzheimer's disease using pharmacological chaperones to increase the activity of gangliosidases
MX368459B (es) 2009-10-19 2019-10-03 Amicus Therapeutics Inc Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
CN102647905B (zh) 2009-10-19 2015-09-09 阿米库斯治疗学公司 用于预防和/或治疗溶酶体贮积失调的新颖组合物
ES2600932T3 (es) * 2009-10-27 2017-02-13 Erytech Pharma Composición para inducir una tolerancia inmunitaria específica
EP2502068B1 (en) * 2009-11-17 2016-02-10 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
SI2796457T1 (sl) * 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
CA2817011C (en) * 2010-11-08 2019-04-02 Callidus Biopharma, Inc. Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
EP3626255A1 (en) 2010-11-30 2020-03-25 Orphazyme A/S Methods for increasing intracellular activity of hsp70
ES2807502T3 (es) * 2011-03-11 2021-02-23 Amicus Therapeutics Inc Regímenes de dosificación para el tratamiento de la enfermedad de Fabry
EP2533051A1 (en) * 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
KR20140135222A (ko) 2012-03-07 2014-11-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
WO2013148103A1 (en) 2012-03-27 2013-10-03 Amicus Therapeutics, Inc. Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system
SI2844279T1 (sl) * 2012-05-03 2021-04-30 Amicus Therapeutics, Inc. Dozirni režimi za zdravljenje Pompejeve bolezni
US9694056B2 (en) 2012-07-17 2017-07-04 Amicus Therapeutics, Inc. α-galactosidase A and 1-deoxygalactonojirimycin co-formulation
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
US9675627B2 (en) 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
ES2881860T3 (es) 2014-09-15 2021-11-30 Orphazyme As Formulación de arimoclomol
RS65066B1 (sr) 2014-09-30 2024-02-29 Amicus Therapeutics Inc Visoko potentna kisela alfa-glukozidaza sa pojačanim ugljenim hidratima
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US10179128B2 (en) * 2015-08-31 2019-01-15 Amicus Therapeutics, Inc. Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
WO2017117407A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
JP6438421B2 (ja) * 2016-02-17 2018-12-12 ファナック株式会社 電動機のステータ
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
KR20240001291A (ko) 2016-03-30 2024-01-03 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
WO2017178029A1 (en) 2016-04-13 2017-10-19 Orphazyme Aps Heat shock proteins and cholesterol homeostasis
LT3448382T (lt) 2016-04-29 2021-04-12 Orphazyme A/S Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
EP3615509A1 (en) 2017-04-25 2020-03-04 Amicus Therapeutics, Inc. Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
CN117357524A (zh) * 2017-05-30 2024-01-09 阿米库斯治疗学公司 治疗具有肾损害的法布里患者的方法
CA3065298A1 (en) 2017-05-30 2018-12-06 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
AU2019217868A1 (en) 2018-02-06 2020-10-01 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
JP2022536687A (ja) * 2019-06-11 2022-08-18 アミカス セラピューティックス インコーポレイテッド 腎機能障害を有する患者のファブリー病を治療する方法
MX2022001623A (es) 2019-08-07 2022-03-02 Amicus Therapeutics Inc Metodos para tratar la enfermedad de fabry en pacientes que tienen una mutacion en el gen gla.
AU2021380947B2 (en) 2020-11-19 2023-12-14 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
EP2332567B1 (en) * 2003-01-31 2015-04-08 The Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
US7446098B2 (en) 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
EP2932982B1 (en) * 2005-05-17 2018-10-03 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
EP1888068B1 (en) * 2005-06-08 2014-05-21 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
US7955262B2 (en) 2005-07-26 2011-06-07 Syneron Medical Ltd. Method and apparatus for treatment of skin using RF and ultrasound energies
KR20080033463A (ko) * 2005-07-27 2008-04-16 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 단백질 미스폴딩을 보정하는 작은 화합물 및 그의 용도
ES2464527T7 (es) * 2006-05-16 2015-09-14 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
EP2142197A4 (en) 2007-03-30 2010-11-10 Amicus Therapeutics Inc PROCESS FOR THE TREATMENT OF FABRY DISEASE USING PHARMACOLOGICAL CHAPERONS

Also Published As

Publication number Publication date
US9056101B2 (en) 2015-06-16
AU2008245578A1 (en) 2008-11-06
EP2150254A4 (en) 2010-11-10
JP2010525084A (ja) 2010-07-22
WO2008134628A3 (en) 2010-01-14
IL201733A0 (en) 2010-06-16
WO2008134628A2 (en) 2008-11-06
US20150352093A1 (en) 2015-12-10
CA2685332A1 (en) 2008-11-06
US20100266571A1 (en) 2010-10-21
EP2150254A2 (en) 2010-02-10

Similar Documents

Publication Publication Date Title
MX2009011473A (es) Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
AU2011328009A8 (en) Compounds and methods for treating pain
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
IN2014DN09434A (es)
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
IN2012DN06720A (es)
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
BR112013026202A2 (pt) composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tank
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
NZ631144A (en) Compositions and methods for transmucosal absorption
MX345535B (es) Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
MX2014005351A (es) Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
EP2582682A4 (en) METHOD FOR THE TREATMENT OF LUNG DISEASES
MX2015004362A (es) Derivados de ketamina.
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
PH12016500136B1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
EA200970816A1 (ru) Новая лекарственная форма
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal